Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy

Study Overview
=================
Brief Summary
-----------------
Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). We aim to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.

Detailed Description
-----------------
Acute CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics are related to the eventual resolution of subretinal fluid. Such relation can shed light on pathophysiological disease mechanisms and constitute a biomarker for disease activity. Chronic CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics will change in response to standard treatment with PDT. The research of such changes will increase the understanding of the treatment response. This knowledge will help in the effort to understand the why some patients are non-responsive to the treatment.

Official Title
-----------------
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy

Conditions
-----------------
Central Serous Chorioretinopathy

Intervention / Treatment
-----------------
* Drug: Verteporfin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- Able to sign informed consent Possible to obtain fundus imaging Acute CSC ˂4 months of duration in one eye, defined as: Subfoveal presence of SRF on OCT Present attack is 1st -3rd attack of CSC b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT Chronic CSC ≥4 months of duration in one eye, defined as: Subfoveal presence of SRF on OCT Subjective visual loss/symptoms Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT Patient history and examination consistent with chronic CSC Exclusion Criteria: History of retinal disease other than CSC (e.g. retinal detachment) Contraindications for FA, ICGA or PDT (only for chronic CSC)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute<br>Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months. | |
| Chronic<br>Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months. | Drug: Verteporfin<br>* Chronic CSC are receiving one treatment before the observation period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Choroidal blood flow1 | Change in mean blur rate | 6 months | 
| Choroidal blood flow2 | Change in pulse wave form analysis | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Choroidal morphology | Change in choroidal density | 6 months | 
| Choroidal morphology | Change in choroidal thickness | 6 months |